The present invention relates to a method for detecting renal disease and for assessing the efficacy of dialysis treatment using imaging agents having desirable in vivo properties.

The present invention relates to a method for detecting renal disease and for assessing the efficacy of dialysis treatment using imaging agents having desirable in vivo properties.

The present disclosure relates to compounds of Formula (I′):

##STR00001##

and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.

A compound, comprising a segment having the formula (AA) or (BB):

##STR00001## wherein C.sub.31 and C.sub.32 are carbons (C), wherein R.sub.32 and R.sub.33 are both hydrogens or collectively forms a carbonyl with C.sub.31, wherein R.sub.34 and R.sub.35 are both hydrogens or collectively forms a carbonyl with C.sub.32, wherein X is oxygen (O) or nitrogen attached to an organic residue, wherein R.sub.31 is a hydrogen, a hydroxymethyl, a halogen-substituted methyl, or an unsubstituted methylene —CH.sub.2— group covalently and directly bonded to X, wherein dashed lines (---) represent optional covalent bonds to satisfy valence.

A process for preparing a nitrated compound, including the step of reacting a compound (A) including at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein the heteroaromatic ring includes at least one heteroatom selected from the group consisting of oxygen, sulfur, phosphor, selenium and nitrogen, with a compound of formula (I)

##STR00001##

wherein Y is selected from the group consisting of hydrogen and nitro.

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. ##STR00001##

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. ##STR00001##

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

##STR00001##

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

##STR00001##

Provided are certain TRK inhibitors of formula (I): ##STR00001##
pharmaceutical compositions thereof, and methods of use thereof.